Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
6.42B
Market cap6.42B
Price-Earnings ratio
42.57
Price-Earnings ratio42.57
Dividend yield
Dividend yield
Average volume
2.51M
Average volume2.51M
High today
$38.97
High today$38.97
Low today
$38.01
Low today$38.01
Open price
$38.50
Open price$38.50
Volume
1.31M
Volume1.31M
52 Week high
$38.97
52 Week high$38.97
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

Alkermes(ALKS) stock is priced at $38.53, giving the company a market capitalization of 6.42B. It carries a P/E multiple of 42.57.

As of 2026-05-13, Alkermes(ALKS) stock has fluctuated between $38.01 and $38.97. The current price stands at $38.53, placing the stock +1.4% above today's low and -1.1% off the high.

Alkermes(ALKS) shares are trading with a volume of 1.31M, against a daily average of 2.51M.

During the past year, Alkermes(ALKS) stock moved between $25.17 at its lowest and $38.97 at its peak.

During the past year, Alkermes(ALKS) stock moved between $25.17 at its lowest and $38.97 at its peak.

ALKS News

TipRanks 3h
Alkermes price target raised to $48 from $45 at Baird

Baird analyst Luke Herrmann raised the firm’s price target on Alkermes (ALKS) to $48 from $45 and keeps an Outperform rating on the shares. The firm updated its...

Benzinga 22h
Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

The stock’s movement comes as the Healthcare sector is currently the best-performing sector, gaining 2.43%, while the broader market is mixed, with the S&P 500...

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles
Simply Wall St 22h
Alkermes' Conservative Accounting Might Explain Soft Earnings

Soft earnings didn't appear to concern Alkermes plc's ( ) shareholders over the last week. We did some digging, and we believe the earnings are stronger than th...

Alkermes' Conservative Accounting Might Explain Soft Earnings

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
18.8%
Sell
0%

More ALKS News

TipRanks 1d
Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study

Alkermes (ALKS) announced positive topline results from the REVITALYZ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluat...

TipRanks 1d
Alkermes Reports Positive Phase 3 Results for LUMRYZ

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Simply Wall St 3d
Evaluating Alkermes Valuation After Recent Share Price Momentum

Advertisement Context for Alkermes stock Alkermes (ALKS) has been on investors’ radar after recent share price moves, with the stock showing gains over the pa...

Evaluating Alkermes Valuation After Recent Share Price Momentum
Simply Wall St 4d
Is It Time To Reassess Alkermes After Strong Recent Share Price Gains

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implyi...

Is It Time To Reassess Alkermes After Strong Recent Share Price Gains
TipRanks 6d
Alkermes Advances Brilliance NT2 Phase 3 Trial, Raising Interest in Narcolepsy Market

Alkermes plc (ALKS) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisio...

Benzinga 7d
Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday. The company posted quarterly losses of 40 cents per share which beat the analy...

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.